Publikationen (24) Publikationen von LAURA ABAD MANTECA

2023

  1. Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID-19 pneumonia: An open-label randomised trial

    European Journal of Clinical Investigation, Vol. 53, Núm. 1

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  2. Utilidad del índice de comorbilidad de Charlson en personas ancianas. Concordancia con otros índices de comorbilidad

    Revista Clínica de Medicina de Familia, Vol. 14, Núm. 2, pp. 64-70

2018

  1. Relationship between the FRAX index and physical and cognitive functioning in older people

    Annals of Medicine, Vol. 50, Núm. 6, pp. 538-543

  2. Role of Bone Morphogenetic Protein 2 Polymorphisms in Bone Mineral Density after the Start of Treatment with Atorvastatin

    Basic and Clinical Pharmacology and Toxicology, Vol. 123, Núm. 6, pp. 766-769

2016

  1. Relationship among angiotensin-converting enzyme polymorphism, cardiovascular risk, and osteoporotic fractures

    European Journal of Rheumatology, Vol. 3, Núm. 1, pp. 10-12

2015

  1. Trombosis venosa inusual como primera manifestación de neoplasia pulmonar

    Archivos de Bronconeumologia

2014

  1. Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin

    Rheumatology International, Vol. 34, Núm. 8, pp. 1073-1077

2010

  1. Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin

    International Journal of Cardiology, Vol. 145, Núm. 1, pp. 164-165

  2. Vitamin D levels and lipid response to atorvastatin

    International Journal of Endocrinology, Vol. 2010

2009

  1. Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene

    Endocrine Journal, Vol. 56, Núm. 2, pp. 221-225

2008

  1. Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome

    International Journal of Cardiology, Vol. 129, Núm. 1, pp. 144-145

  2. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome

    European Review for Medical and Pharmacological Sciences, Vol. 12, Núm. 2, pp. 83-88

  3. Effect of the TNFα-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome

    Annals of Nutrition and Metabolism, Vol. 53, Núm. 2, pp. 117-121

2007

  1. Effect of β-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction

    Joint Bone Spine, Vol. 74, Núm. 3, pp. 259-262

  2. Effects of Atorvastatin on Vitamin D Levels in Patients With Acute Ischemic Heart Disease

    American Journal of Cardiology, Vol. 99, Núm. 7, pp. 903-905

  3. Effet des bêtabloquants sur la masse osseuse et les propriétés biomécaniques du col fémoral après un infarctus du myocarde chez les malades de sexe masculin

    Revue du Rhumatisme (Edition Francaise), Vol. 74, Núm. 5, pp. 475-478

  4. Ghrelin and bone mass in postmenopausal hypertensive women

    Annals of Nutrition and Metabolism, Vol. 51, Núm. 3, pp. 223-227

2006

  1. Effects of statins on bone markers bone mineral density and fractures. Possible role in osteoporosis treatment

    Current Pharmaceutical Analysis, Vol. 2, Núm. 2, pp. 161-168

2005

  1. Effect of atorvastatin to RANKL/OPG system in patients with acute coronary syndrome

    Journal of Applied Research, Vol. 5, Núm. 4, pp. 569-574